# Official Journal C 32I/2021

| | ISSN 1977-091X |
| --- | --- |
| Official Journal
  of the European Union | C 032I |
| | |
| English edition | Information and Notices | Volume 6429 January 2021 |

ISSN 1977-091X

Official Journal

of the European Union

C 032I

English edition

Information and Notices

Volume 6429 January 2021

---

| Contents | page |
| --- | --- |
| | IV   Notices |
| | NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES |
| | European Commission |
| 2021/C 32 I/01 | Summary of European Union decisions on marketing authorisations in respect of medicinal products on 29 January 2021(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council) | 1 |

Contents

page

IV   Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

2021/C 32 I/01

Summary of European Union decisions on marketing authorisations in respect of medicinal products on 29 January 2021(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)

(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)

1

---

| EN | |
| --- | --- |

EN

---

IV Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

| 29.1.2021 | EN | Official Journal of the European Union | CI 32/1 |
| --- | --- | --- | --- |

29.1.2021

EN

Official Journal of the European Union

CI 32/1

---

Summary of European Union decisions on marketing authorisations in respect of medicinal products on 29 January 2021

(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council (1))

(2021/C 32 I/01)

| — | Issuing of a marketing authorisation (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted













  Date of the decision | Name of the medicinal product | INN (International Non-Proprietary Name) | Holder of the marketing authorisation | Number of the entry in the Community Register | Pharmaceutical form | ATC code (Anatomical Therapeutic Chemical Code) | Date of notification |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 29.1.2021 | COVID-19 Vaccine AstraZeneca | COVID-19 Vaccine (ChAdOx1-S [recombinant]) | AstraZeneca AB |
| 151 85 Södertälje, Sverige |

—

Issuing of a marketing authorisation (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted

Date of the decision

Name of the medicinal product

INN (International Non-Proprietary Name)

Holder of the marketing authorisation

Number of the entry in the Community Register

Pharmaceutical form

ATC code (Anatomical Therapeutic Chemical Code)

Date of notification

29.1.2021

COVID-19 Vaccine AstraZeneca

COVID-19 Vaccine (ChAdOx1-S [recombinant])

AstraZeneca AB

151 85 Södertälje, Sverige

EU/1/21/1529

Suspension for injection

J07BX03

29.1.2021

Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:

| European Medicines Agency |
| --- |
| Domenico Scarlattilaan 6 |
| 1083 HS Amsterdam |
| NETHERLANDS |

European Medicines Agency

Domenico Scarlattilaan 6

1083 HS Amsterdam

NETHERLANDS

---

(1)  OJ L 136, 30.4.2004, p. 1.

---